Stoke Therapeutics shareholders elect three Class III directors at 2025 annual meeting

Stoke Therapeutics, Inc.

Edward M. Kaye, Seth L. Harrison, and Arthur O. Tzianabos elected as Class III directors with ~29.2M votes each.
Ratification of KPMG as independent auditor for FY2025 approved with 38.7M for vs 67.8K against.
Non-binding advisory vote on named executive officer compensation approved with 30.5M for vs 2.9M against.
Advisory vote on frequency of future say-on-pay set at one year (33.1M votes) as preferred frequency.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.